FGFR-FC fusion proteins and the use thereof
AssigneeRemegen Co., Ltd.
InventorsJianmin Fang, Dong Li
Life of this patent
Estimating the term…
Abstract
The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.
Claims8
An isolated soluble fusion protein which binds fibroblast growth factor (FGF), comprising a region derived from the extracellular domain of FGFR and an immunoglobulin Fc region, said isolated soluble fusion protein contains no acidic box, which is set forth in amino acid residues 126 to 133 of SEQ ID NO:1, and said region derived from the extracellular domain of FGFR consists of:
- a part derived from an intermediate functional sequence (IFS) of an Ig-like domain of FGFR, a second Ig-like domain (D2) of FGFR, and a third Ig-like domain (D3) of FGFR,
- wherein the sequence of the part derived from the IFS is a sequence of amino acid residues corresponding to position 142 to 162, 143 to 162, 144 to 162, 145 to 162, 146 to 162, 147 to 162, or 148 to 162 of SEQ ID NO:
- 1;
- D2 has a sequence of amino acid residues corresponding to position 163 to position 247 of SEQ ID NO:
- 1;
- D3 has a sequence of amino acid residues corresponding to position 270 to position 359 of SEQ ID NO:
- 1;
- and
- the part derived from IFS, D2, D3 and the immunoglobulin Fc region are linked directly or by a linker.
Dependencies are inferred from the claim text.